Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib

Detalles Bibliográficos
Autores principales: Zhang, Hao, Hu, Yongxian, Chang, Alex H., Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965727/
https://www.ncbi.nlm.nih.gov/pubmed/31988993
http://dx.doi.org/10.1016/j.reth.2019.11.003
_version_ 1783488669953294336
author Zhang, Hao
Hu, Yongxian
Chang, Alex H.
Huang, He
author_facet Zhang, Hao
Hu, Yongxian
Chang, Alex H.
Huang, He
author_sort Zhang, Hao
collection PubMed
description
format Online
Article
Text
id pubmed-6965727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Japanese Society for Regenerative Medicine
record_format MEDLINE/PubMed
spelling pubmed-69657272020-01-27 Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib Zhang, Hao Hu, Yongxian Chang, Alex H. Huang, He Regen Ther Letter to the Editor Japanese Society for Regenerative Medicine 2020-01-14 /pmc/articles/PMC6965727/ /pubmed/31988993 http://dx.doi.org/10.1016/j.reth.2019.11.003 Text en © 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Zhang, Hao
Hu, Yongxian
Chang, Alex H.
Huang, He
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title_full Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title_fullStr Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title_full_unstemmed Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title_short Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib
title_sort successful treatment of t315i bcr-abl mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor t cell therapy followed by dasatinib
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965727/
https://www.ncbi.nlm.nih.gov/pubmed/31988993
http://dx.doi.org/10.1016/j.reth.2019.11.003
work_keys_str_mv AT zhanghao successfultreatmentoft315ibcrablmutatedlymphoidblastphasechronicmyeloidleukemiawithchimericantigenreceptortcelltherapyfollowedbydasatinib
AT huyongxian successfultreatmentoft315ibcrablmutatedlymphoidblastphasechronicmyeloidleukemiawithchimericantigenreceptortcelltherapyfollowedbydasatinib
AT changalexh successfultreatmentoft315ibcrablmutatedlymphoidblastphasechronicmyeloidleukemiawithchimericantigenreceptortcelltherapyfollowedbydasatinib
AT huanghe successfultreatmentoft315ibcrablmutatedlymphoidblastphasechronicmyeloidleukemiawithchimericantigenreceptortcelltherapyfollowedbydasatinib

Ejemplares similares